171 related articles for article (PubMed ID: 30427809)
21. Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia.
Oesterhus R; Aarsland D; Soennesyn H; Rongve A; Selbaek G; Kjosavik SR
Int J Geriatr Psychiatry; 2017 Feb; 32(2):183-192. PubMed ID: 26924491
[TBL] [Abstract][Full Text] [Related]
22. When Should Iatrogenic Polypharmacy Be Considered a Disease?
Wieseler C
AMA J Ethics; 2018 Dec; 20(12):E1133-1138. PubMed ID: 30585575
[TBL] [Abstract][Full Text] [Related]
23. Correlates of major medication side effects interfering with daily performance: results from a cross-sectional cohort study of older psychiatric patients.
Tveito M; Correll CU; Bramness JG; Engedal K; Lorentzen B; Refsum H; Høiseth G
Int Psychogeriatr; 2016 Feb; 28(2):331-40. PubMed ID: 26412479
[TBL] [Abstract][Full Text] [Related]
24. Medical treatment of psychiatric patients: possible polypharmacy problems.
Norton JC; Ludwig AM
Hosp Community Psychiatry; 1982 Apr; 33(4):305-7. PubMed ID: 7076147
[No Abstract] [Full Text] [Related]
25. Factors Associated with Potential Drug-Drug Interactions in Patients Attended in Primary Health Care: A Focus on Mental Health.
Borges TL; Vedana KGG; Castilho ECD; Miasso AI
Issues Ment Health Nurs; 2017 Sep; 38(9):769-774. PubMed ID: 28766975
[TBL] [Abstract][Full Text] [Related]
26. Drug-drug interactions in general hospital and psychiatric hospital in-patients prescribed psychotropic medications.
Sinclair LI; Davies SJ; Parton G; Potokar JP
Int J Psychiatry Clin Pract; 2010 Sep; 14(3):212-9. PubMed ID: 24917322
[TBL] [Abstract][Full Text] [Related]
27. Screening indicators to evaluate the clinical significance of drug-drug interactions in polypharmacy among older adults with psychiatric disorders: a delphi study.
Liu Y; Li X; Yang M; Ding Y; Ji M
BMC Psychiatry; 2024 Jun; 24(1):417. PubMed ID: 38834965
[TBL] [Abstract][Full Text] [Related]
28. Polypharmacy and drug-drug interactions among older and younger male prisoners in Switzerland.
Annaheim B; Wangmo T; Bretschneider W; Handtke V; Elger BS; Belardi A; Meyer AH; Hösli R; Lutters M
Int J Prison Health; 2019 Aug; 15(3):250-261. PubMed ID: 31329038
[TBL] [Abstract][Full Text] [Related]
29. Polypharmacy in psychiatric practice in the Canary Islands.
De las Cuevas C; Sanz EJ
BMC Psychiatry; 2004 Jul; 4():18. PubMed ID: 15236661
[TBL] [Abstract][Full Text] [Related]
30. Psychotropic drug versus psychotropic drug-update.
Strain JJ; Chiu NM; Sultana K; Karim A; Caliendo G; Mustafa S; Strain JJ
Gen Hosp Psychiatry; 2004; 26(2):87-105. PubMed ID: 15038926
[TBL] [Abstract][Full Text] [Related]
31. A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications.
Brouillette J; Nattel S
Can J Cardiol; 2017 Dec; 33(12):1577-1586. PubMed ID: 29173600
[TBL] [Abstract][Full Text] [Related]
32. Psychotropic medication use in children and adolescents in an inpatient setting.
Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V
Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
[TBL] [Abstract][Full Text] [Related]
34. Polypharmacy: when is it rational?
Preskorn SH; Lacey RL
J Psychiatr Pract; 2007 Mar; 13(2):97-105. PubMed ID: 17414685
[TBL] [Abstract][Full Text] [Related]
35. Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists.
Kearns MA; Hawley KM
J Psychiatr Pract; 2014 Nov; 20(6):438-47. PubMed ID: 25406048
[TBL] [Abstract][Full Text] [Related]
36. Statin drug interactions and related adverse reactions: an update.
Bellosta S; Corsini A
Expert Opin Drug Saf; 2018 Jan; 17(1):25-37. PubMed ID: 29058944
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Psychotropic Polypharmacy Among Outpatients With Psychiatric Disorders and Intellectual Disability.
Lunsky Y; Modi M
Psychiatr Serv; 2018 Feb; 69(2):242-246. PubMed ID: 29089006
[TBL] [Abstract][Full Text] [Related]
38. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders.
Medhekar R; Aparasu R; Bhatara V; Johnson M; Alonzo J; Schwarzwald H; Chen H
Res Social Adm Pharm; 2019 Apr; 15(4):395-403. PubMed ID: 29929905
[TBL] [Abstract][Full Text] [Related]
39. Psychiatric polypharmacy: a clinical approach based on etiology and differential diagnosis.
Freudenreich O; Kontos N; Querques J
Harv Rev Psychiatry; 2012; 20(2):79-85. PubMed ID: 22512741
[TBL] [Abstract][Full Text] [Related]
40. Drug-drug interactions between COVID-19 therapeutics and psychotropic medications.
Cuomo A; Barillà G; Serafini G; Aguglia A; Amerio A; Cattolico M; Carmellini P; Spiti A; Fagiolini A
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):925-936. PubMed ID: 38032183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
